Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$18.82 USD
+0.13 (0.70%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $18.83 +0.01 (0.05%) 7:20 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.82 USD
+0.13 (0.70%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $18.83 +0.01 (0.05%) 7:20 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Wall Street Analysts Predict a 45% Upside in Syndax (SNDX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 44.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's What Could Help Syndax (SNDX) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
What Makes Syndax (SNDX) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Syndax (SNDX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Can Syndax (SNDX) Climb 39% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 39.1% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Incyte (INCY) Outperforms YTD: Will the Momentum Continue?
by Zacks Equity Research
Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
by Zacks Equity Research
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.
Teva Pharmaceutical (TEVA) Names Richard Francis as New CEO
by Zacks Equity Research
Teva Pharmaceutical (TEVA) appoints Richard Francis as the company's new president and chief executive officer, effective from Jan 1, 2023.
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
by Zacks Equity Research
The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023. Stock up.
Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?
by Zacks Equity Research
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down
by Zacks Equity Research
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.
Immunovant (IMVT) Rises More Than 150% in 3 Months: Here's How
by Zacks Equity Research
Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion
by Zacks Equity Research
Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.
Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort
by Zacks Equity Research
Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing
by Zacks Equity Research
Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
by Zacks Equity Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Syndax (SNDX) Climb 48% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 47.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate
by Zacks Equity Research
Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syndax Pharmaceuticals (SNDX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
by Zacks Equity Research
Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF
by Zacks Equity Research
The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.